Table 4.
Absolute difference in events per 1000 patients treated per year in the various regional subgroups*
| Comparison | Stroke/SEE | Major bleeding |
|---|---|---|
| Risk difference (95%CI) | Risk difference (95%CI) | |
| All Europe (n = 32 089) | ||
| Dabigatran vs. warfarin | 0 (−5 to 5) | −2 (−8 to 4) |
| Rivaroxaban vs. warfarin | −2 (−8 to 3) | −2 (−8 to 3) |
| Apixaban vs. warfarin | −1 (−4 to 3) | −4 (−9 to 0.4) |
| Edoxaban vs. warfarin | 2 (−2 to 5) | −7 (−12 to −2) |
| All DOACs vs. warfarin | 0 (−2 to 2) | −4 (−7 to − 2) |
| Western Europe (n = 13 676) | ||
| Dabigatran vs. warfarin | −2 (−7 to 5) | −4 (−12 to 3) |
| Rivaroxaban vs. warfarin | −1 (−12 to 10) | −11 (−24 to 1) |
| Apixaban vs. warfarin | 1 (−3 to 6) | −2 (−9 to 6) |
| Edoxaban vs. warfarin | 5 (−1 to 12) | −6 (−17 to 4) |
| All DOACs vs. warfarin | 1 (−1 to 4) | −5 (−10 to − 0.1) |
| Eastern Europe (n = 18 413) | ||
| Dabigatran vs. warfarin | 3 (−5 to 10) | 1 (−8 to 11) |
| Rivaroxaban vs. warfarin | −3 (−10 to 4) | 1 (−5 to 7) |
| Apixaban vs. warfarin | −3 (−9 to 4) | −7 (−14 to −1) |
| Edoxaban vs. warfarin | 0 (−4 to 4) | −8 (−13 to −3) |
| All DOACs vs. warfarin | −1 (−4 to 2) | −4 (−9 to 1) |
| North‐America (n = 18 369) | ||
| Dabigatran vs. warfarin | −4 (−8 to 1) | 0 (−9 to 9) |
| Rivaroxaban vs. warfarin | −1 (−10 to 8) | 19 (5 to 34) |
| Apixaban vs. warfarin | −4 (−9 to 1) | −9 (−17 to −1) |
| Edoxaban vs. warfarin | −6 (−10 to −1) | −5 (−14 to 5) |
| All DOACs vs. warfarin | −4 (−7 to − 2) | 0 (−10 to 10) |
| Latin‐America (n = 8963) | ||
| Dabigatran vs. warfarin | −2 (−15 to 10) | −6 (−23 to 11) |
| Rivaroxaban vs. warfarin | −5 (−17 to 7) | 4 (−8 to 16) |
| Apixaban vs. warfarin | −4 (−10 to 3) | −12 (−21 to −4) |
| Edoxaban vs. warfarin | −11 (−19 to −3) | −10 (−20 to 1) |
| All DOACs vs. warfarin | −6 (−10 to − 2) | −7 (−14 to − 0.1) |
| Asia Pacific, other (n = 13 542) | ||
| Dabigatran vs. warfarin | −10 (−18 to −2) | −10 (−20 to −0.2) |
| Rivaroxaban vs. warfarin † | −5 (−15 to 4) | −8 (−19 to 2) |
| Apixaban vs. warfarin | −12 (−21 to −3) | −19 (−28 to −9) |
| Edoxaban vs. warfarin | −8 (−15 to −1) | −5 (−16 to 5) |
| All DOACs vs. warfarin | −9 (−13 to − 5) | −11 (−16 to − 6) |
CI, confidence interval; DOAC, direct oral anticoagulants; SEE, systemic embolic events.
*
Random effects model. The base case excludes the 30 mg/15 mg edoxaban dose.
†
Includes pooled data from ROCKET‐AF (subgroup of Asian patients) and J ROCKET.